The ESR1-mutated metastatic breast cancer space is being reshaped by novel oral SERDs and targeted agents, including Giredestrant, Camizestrant, Palazestrant, Lasofoxifene, AND-019, H3B-6545, and VEPPANU, with several candidates in development or recently approved.

These therapies are advancing across companies and stages, driving a broader shift toward precision oncology in HR-positive/HER2-negative breast cancer.

Clinical trials suggest multiple agents from this group are expected to reach the market during the forecast period, potentially altering market dynamics.

In 2025, about 1.3 million people were diagnosed with HR-positive breast cancer in the seven major markets.

Roughly 40% of advanced breast cancer patients develop ESR1 mutations during first-line therapy, undermining treatment effectiveness.

The ESR1-mutated metastatic breast cancer market is projected to grow at a 9.6% CAGR from 2026 to 2036, fueled by new oral SERDs, targeted agents, and expanding precision oncology adoption.

In the 7MM, the current ESR1-mutated metastatic breast cancer treatment market is about USD 1.5 billion, with the U.S. as the largest contributor, and ESR1 mutations are found in an estimated 20–40% of aromatase inhibitor–exposed patients.

Advancements in diagnostics, including liquid biopsy and next-generation sequencing, enable real-time detection and monitoring of ESR1 mutations to support precision treatment decisions.

VEPPANU (vepdegestrant) marks the first FDA-approved PROTAC therapy for ESR1-mutated ER+/HER2- advanced or metastatic breast cancer, signaling a shift toward protein degradation strategies.

There remains a need for effective endocrine therapy options post-endocrine therapy, including after CDK4/6 inhibitors, with ongoing trials aiming to extend progression-free survival in ESR1-mutated disease.

Key companies active in this space include Roche/Genentech, AstraZeneca, Olema Pharmaceuticals, Sermonix, Kind Pharmaceuticals, Eisai, Lilly, Arvinas, Pfizer, among others.

The report highlights continued entrants (Giredestrant, Camizestrant, Palazestrant, Lasofoxifene, AND-019, H3B-6545, INLURIYO, ORSERDU, VEPPANU) as primary drivers of market evolution and potential growth opportunities.